Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
1
II-B. MEDICINAL CHEMISTRY
0
20
40
60
80
100
Abso
rban
ce
Plate #
Drug Discovery CheckpointsTarget Identification1 gggcgtggag gagcccaccg accggagacc atttggggcc tggagatgcc atcggagggc61 aggagctcat cctggagagg ccaccgtaag gcctgacctg ggcctgggga gcttggcttg121 aggaagctnt gggccgacca aggccgccag gagatgggt
Target Characterization
Lead Definition
Lead Optimization
Candidate EvaluationDrug Formulation
Clinical Testing
1-2 y2-6 y
7 y
Dr. P. Wipf Chem 2320 4/5/2007
2
Stages in the Drug Discovery Process
Lombardino, J. G.; Lowe, J. A., "A guide to drug discovery: The role of the medicinal chemist in drugdiscovery - then and now." Nature Rev. Drug Disc. 2004, 3, 853-862.
10 Year Trends in Biomedical Research
50% Decline in newproduct submissions
250% increase in R & Dexpenditures
NME = New molecular entitiesBLA = Biologics
FDA Report March 2004: Innovation or Stagnation, Challenge and Opportunity on theCritical Path to New Medical ProductsWoosley & Cossman. Clin Pharm Therap. 81:129, 2007
Dr. P. Wipf Chem 2320 4/5/2007
3
Drug Potencies & Rate of Target Innovation
High Target Innovation
Re-Use of Established Mechanisms
• Ca. 130 “privileged druggable domains” cover all current drug targets (vs. total number ofprotein families (16,000) and folds (10,000).• Of ca. 1,620 distinct human protein sequences are linked to a genetic disease, only 105 areactual drug targets.• Target innovation is slow - The average rate over the past 20 years has been quite constantat 5 new “drugged” targets per year.• The first approved indications for drugs acting on new targets are usually orphan diseases.
Median affinity = 20 nM
The State-of-the-Art in Drug Discovery:
Small, incremental advances in fundamental biology,chemistry, and clinical sciences
“The Most Fruitful Basis for the Discovery of a NewDrug is to Start with an Old Drug”
James Black - 1988 Nobel Prize in Physiology andMedicine
Dr. P. Wipf Chem 2320 4/5/2007
4
Current Drug Discovery Challenges
In Search of New Leads…..
Dr. P. Wipf Chem 2320 4/5/2007
5
Medicinal Chemistry
The science that deals with the discovery or designof new therapeutic agents and their developmentinto useful medicines.
It involves:
• Organic Synthesis
• Biological Target Identification & AssayDevelopment
• Structure-Activity Relationships (SAR)
• Absorption, distribution, metabolism, andexcretion (ADME)
Why Is Structural Diversity An Issue?
Dr. P. Wipf Chem 2320 4/5/2007
6
‘Drug-like’ & ‘Lead-like’ Properties
‘Drug-like’ & ‘Lead-like’ Properties
Dr. P. Wipf Chem 2320 4/5/2007
7
‘Drug-like’ & ‘Lead-like’ Properties• Reactive functionalities should be filtered:
Where Did (Do) Our Drugs Come From?
Dr. P. Wipf Chem 2320 4/5/2007
8
Screening of natural product extracts
High-Pressure AcceleratedSolvent Extractor System
DCM & MeOHExtracts
Parallel HPLC
HT Solvent Concentrator
Multiwell PlatesFor HTS
Examples of Natural Products as Leads &Drugs
Cardiac glycosides, morphine, quinine, salicylic acid, taxol,camptothecin, penicillin, cyclosporin A, warfarin, artemisine….
O
HO
RO
N
R = H: MorphineR = Me: Codeine
(pain killer)
HO
H H
OH
H
HO
H H
OH
HH
17-ethynylestradiol norethindrone
(the "Pill"; contraceptive)
Clarithromycin(antibacterial)
O
O
O
OH
OMeHO
O
O
O
OMe
OH
OHO
N
HOO N
S
O
NH2
CO2H
HH
Ampicillin(antibiotic)
N
O
O
OH
CO2H
Clavulanic acid(!-lactamase inhibitor)
Augmentin(antibiotic)
NN
O
O
O
N
HN
NNH
HN
N
O
O
O
OO
O
N
O
OH
N
O
NH
Cyclosporine A
1 2
3
4
567
89
1011
Dr. P. Wipf Chem 2320 4/5/2007
9
Drug DiscoveryOne way to “discover” drugs
Serendipitous Drug Discovery
Dr. P. Wipf Chem 2320 4/5/2007
10
Serendipitous Discovery of Librium without a Lead
In 1955 Roche set out to prepare a series ofbenzheptoxadiazines as potential new tranquilizerdrugs, but the actual structure was found to be that of aquinazoline 3-oxide.
In 1957, during a lab cleanup, a vial containing what wasthought to be the latter compound (X = 7-Cl, R1 = CH2NHCH3,R2 = C6H5) was sent for testing, and it was highly active.
Further analysis showed that the actual structure of the compoundwas the benzodiazepine 4-oxide, Librium, presumably producedin an unexpected reaction of the corresponding chloromethylquinazoline 3-oxide with methylamine.
Librium
Dr. P. Wipf Chem 2320 4/5/2007
11
“Me Too” CompoundsCopying existing drugs with only minor chemical variations is usually referred to as“me too” research. Interestingly, sometimes these close analogs demonstrate major(usually unexpected) advantages, like the bioavailable, broad-spectrum lactamase-resistant penicillins, polar H1 antihistamines without sedative side effects, statins,or PDE5 inhibitors.
May & Baker Ltd. (1972)
Turko, I. V.; Ballard, S. A.; Francis,S. H.; Corbin, J. D., "Inhibition ofcyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5)by sildenafil and relatedcompounds." Mol. Pharmacol. 1999,56, 124-130.
Pfizer (1999) Pfizer (1992)
Rational Drug Discovery
Dr. P. Wipf Chem 2320 4/5/2007
12
Structure-Activity Relationships (SARs)
Structurally specific drugs (most drugs):Act at specific sites (receptor or enzyme)Activity/potency susceptible to smallchanges in structure
Structurally nonspecific drugs:No specific site of actionSimilar activities with varied structures(various gaseous anesthetics, sedatives,antiseptics)
Dr. P. Wipf Chem 2320 4/5/2007
13
Example of SAR
Lead: sulfanilamide (R = H)Thousands of analogs synthesized
From clinical trials, various analogs werefound to possess several different activities:
• Antimicrobial• Antidiabetic• Diuretic• Antihypertensive
sulfa drugs
H2N SO2NHR
Sulfadrug SAR
J. Drews Science 287, 1960 -1964 (2000)
Dr. P. Wipf Chem 2320 4/5/2007
14
Rational Drug Discovery - Piroxicam• It took Pfizer ~18 years to develop the anti-inflammatory drugpiroxicam, which was launched in 1980 during the “golden age ofrational drug discovery”.• The starting point for the development was chemistry-driven, i.e. toidentify acidic, but not carboxylic acid-containing (salicylic acid)structurally novel compounds.• Measurement of a physical property (pKa) as well as serum half-life indogs was the guide for the synthesis program.• Several generations of leads were refined and ultimately led to asuccessful structure with an acceptable safety and activity profile:
Bioisosterism
Bioisosteres - substituents or groups withchemical or physical similarities thatproduce similar biological properties.Can attenuate toxicity, modify activity oflead, and/or alter pharmacokinetics oflead.
Dr. P. Wipf Chem 2320 4/5/2007
15
Classical Isosteres1. Univalent atoms and groups
a. CH3 NH2 OH F Clb. Cl PH2 SHc. Br i-Prd. I t-Bu
2. Bivalent atoms and groups
a.
b.
CH2 NH O S Se
CONHR CO2RCOCH2R COSR
3. Trivalent atoms and groups
a.
b.
CH N
P As
4. Tetravalent atoms
C Sia.
b. C N P
5. Ring equivalents
a.
b.
c.
CH CH S (e.g., benzene, thiophene)
CH N (e.g., benzene, pyridine)
O S CH2 NH(e.g., tetrahydrofuran,tetrahydrothiophene,cyclopentane, pyrrolidine)
Do not have thesame number ofatoms and do notfit steric andelectronic rules ofclassical isosteres,but have similarbiological activity.
Non-ClassicalIsosteres
1. Carbonyl group
O
CC
CNNC O
S SO O
SN
O
OR
CN
O CN
CH
NOH
C
NOCH3
C
2. Carboxylic acid group
S
O
O
N
R
HC
OH
OO
S
O
OH P
NH2
OH
O
P
OEt
OH
O O
C NH
CN
ArS
NH
NH
O O
ONH
SAr
O O
O
SNH
SAr
O O
OO
NO
OH
NS
OH
ON
OH
NN
OH
CH3
NH
XO
O O
O
OHN
NN
NH
N
NOH
N N
NOH
N
N OHN
N
OH
OH
F
F
3. Amide group
CNH2
O O
CHN
CNH2
S
CCH2
O OH
CH2 HNC
NH2
O
HNC
O
O
COR
O
HNS
O
ON
CH3
NH2
N
NH2
H2C
Dr. P. Wipf Chem 2320 4/5/2007
16
4. Ester group
COR
O O
SNRR'
O-
O
CN
F
R N
SN
R'
N
ON
R'
N
S
N
R'
NN
O
OR
NN
S
OR
NN
N
OR
R'
N
NN
N
R'N
OOR
5. Hydroxyl group
OH NHCR
O
NHCNH2
O
NHSO2R CH2OH
NHCR CH(CN)2
6. Catechol
HO
HO
HN
NX
HO
O
X = O, NR
N
O
HO
SHN
O
HO
7. Halogen
X CF3 CN N(CN)2 C(CN)3
8. Thioether
S ONC CN
N
CN
9. Thiourea
S
HN NH2
N
HN NH2
CN
HN NH2
NO2N
NH2
SO2NH2
10. Azomethine
NCN
C
11. Pyridine
N
NO2
N+
R NR3
12. Benzene
N N
N S ON
O
N
S
N
O
N
HN
13. Ring equivalents
NO R'
R
RN
O
RR
R'
O
HN
H3C
R
O
O
N
NH
NH2
H
R
14. Spacer group
(CH2)3
15. Hydrogen
H F
Dr. P. Wipf Chem 2320 4/5/2007
17
Examples of Bioisosteric Analogues
Antihistamines
R X (CH2)n Y X = NH, O, CH2
Y = N(CH3)2 (n = 2)
N
NH
(n = 1)
(n = 1, 2)NH
N
Diphenhydramine
(Benadryl)
Fexofenadine(Allegra)
Ph
O
Ph
NNHO
Ph
Ph OH
CO2H
Otaka, A.; Mitsuyama, E.; Watanabe, J.; Watanabe, H.; Fujii, N., "Synthesis of fluorine-containing bioisosterescorresponding to phosphoamino acids and dipeptide units." Biopolymers 2004, 76, 140-149.
Dr. P. Wipf Chem 2320 4/5/2007
18
Gadek, T. R.; Burdick, D. J.; McDowell, R. S.; Stanley, M. S.; Marsters Jr., J. C.;Paris, K. J.; Oare, D. A.; Reynolds, M. E.; Ladner, C.; Zioncheck, K. A.; Lee, W.P.; Gribling, P.; Dennis, M. S.; Skelton, N. J.; Tumas, D. B.; Clark, K. R.; Keating,S. M.; Beresini, M. H.; Tilley, J. W.; Presta, L. G.; Bodary, S. C., "Generation ofan LFA-1 (leukocyte functional antigen–1) antagonist by the transfer of theICAM-1 (intercellular adhesion molecule–1) immunoregulatory epitope to a smallmolecule." Science 2002, 295, 1086-1089.
The interaction of LFA-1 with the ICAM proteins 1, 2, and 3 iscritical to the adhesion, migration, and proliferation oflymphocytes.
A disruption of these protein-protein interactions could lead toagents for the treatment of psoriasis and transplant rejection.
Case Study: Use of a combined rational design - combinatorialchemistry strategy
Rational Drug Discovery - From Hit to Lead
Dr. P. Wipf Chem 2320 4/5/2007
19
An epitope comprising residues E34, K39, M64, Y66,N68, and Q73 within ICAM-1’s first domain was identifiedas essential for its interaction with LFA-1. The function ofthis epitope is embedded in the carboxylic acid, amine,sulfide, phenol, and carboxamide chemical functionalitiesof the amino acid side chains of these six residues andtheir display in three dimensions along one face of theprotein.
Molecules which mimic this epitope could capture the LFA-1 binding specificity and safety inherent in ICAM-1’sfunction as a regulator of the immune system.
Dr. P. Wipf Chem 2320 4/5/2007
20
More or less serendipitously, compound 1 was found to be an inhibitor of LFA-1.
Dr. P. Wipf Chem 2320 4/5/2007
21
Comparison of the inhibition of ICAM-1/LFA-1 binding and theinhibition of mixed lymphocyte reaction (MLR). IC50 values weredetermined from a 4P fit of data from titrations over concentrations of10-3 to 10-10 M. Values reported are the mean±standard deviation forn>2 of experiments run in triplicate. ND, not determined. NA, notapplicable.
Two orthogonal views of the superimposition of compound 4 on the crystalstructure of the first domain of ICAM-1 indicating that compound 4 mimics theICAM-1 epitope. Residues highlighted in blue contribute significantly to LFA-1binding. The E34 side chain of ICAM-1 has been rotated to a low-energyconformation to enhance the overlay with compound 4.
Dr. P. Wipf Chem 2320 4/5/2007
22
Conclusions:
Compounds 2 through 4 appear to be mimics of ICAM-1resulting from the transfer of the ICAM epitope to a smallmolecule.Compound 4 is a potent LFA-1 antagonist, which bindsLFA-1, blocks the binding of ICAM-1, and inhibits LFA-1mediated lymphocyte proliferation and adhesion in vitro.
This work represents the first reduction of a nonlinear,discontinuous but contiguous protein epitope(encompassing five residues spanning three different b-strands across the face of a protein surface) from aprotein to a small molecule.
Structure-Based Design of Potent Non-PeptideMDM2 inhibitors
The pharmacologicalhypothesis:
Ding et al. JACS 2005, 127, 10130.
Dr. P. Wipf Chem 2320 4/5/2007
23
Structure-Based Design of Potent Non-Peptide MDM2 inhibitors
Structure-BasedDesign:
MDM2
Leu26
Phe19
Trp23
Structure-Based Design of Potent Non-Peptide MDM2 inhibitors
Dr. P. Wipf Chem 2320 4/5/2007
24
Structure-Based Design of Potent Non-Peptide MDM2 inhibitors
Structure-Based Design of Potent Non-Peptide MDM2 inhibitors
Structure-Based Strategy:
Dr. P. Wipf Chem 2320 4/5/2007
25
Structure-Based Design of Potent Non-Peptide MDM2 inhibitors
Gene-Family Distribution of Current Drugs
Paolini, G. V.; Shapland, R. H. B.; van Hoorn, W. P.;Mason, J. S.; Hopkins, A. L., "Global mapping ofpharmacological space." Nature Biotechnology 2006, 24,805-815.
There currently are >21,000 drug productsavailable. If you remove duplicate activeingredients, salt forms, supplements, vitamins,imaging agents, this number is reduced to 1,357unique drugs of which 1,204 are “small moleculedrugs” and 166 are “biological” drugs.
Dr. P. Wipf Chem 2320 4/5/2007
26
Further reading:
Lombardino, J. G.; Lowe, J. A., "A guide to drug discovery: The role ofthe medicinal chemist in drug discovery - then and now." Nat. Rev. DrugDisc. 2004, 3, 853-862.Jorgensen, W. L., "The many roles of computation in drug discovery."Science 2004, 303, 1813-1818.Gustafsson, D.; Bylund, R.; Antonsson, T.; Nilsson, I.; Nystroem, J.-E.;Eriksson, U.; Bredberg, U.; Teger-Nilsson, A.-C., "Case history: A neworal anticoagulant: The 50-year challenge." Nat. Rev. Drug Disc. 2004,3, 649-659.
Dr. P. Wipf Chem 2320 4/5/2007